MedTrace Logo

Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study

NCT02263638 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-03-12

No results posted yet for this study

Summary

Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.

Conditions

  • Refractory Hemochromatosis Rheumatism

Interventions

DRUG

Anakinra

One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Pascal Richette · Groupe Hospitalier Lariboisière - Paris

  • Pascal Guggenbuhl · Rennes University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-04
Primary Completion
2018-09-04
Completion
2018-09-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02263638 on ClinicalTrials.gov